Newbury Pharmaceuticals (NEWBRY) Q2 2026 earnings summary

Executive summary

• Net revenue for Q2 was SEK 8.5 million, down from SEK 12.4 million year-over-year; interim period revenue grew 6% to SEK 20.2 million compared to SEK 19.0 million last year.

• EBITDA for Q2 was SEK -3.7 million, and SEK -9.2 million for the interim period, reflecting higher costs in line with sales growth.

• Operating cash flow improved to SEK 2.3 million in Q2 from SEK -6.4 million last year; interim period operating cash flow was SEK -4.3 million.

• Cash position at period end was SEK 10.1 million, with equity at SEK 31.3 million and a solidity ratio of 41%.

Financial highlights

• Q2 net revenue: SEK 8,454k (Q2 prior year: SEK 12,434k); interim period: SEK 20,174k (prior year: SEK 18,972k).

• Q2 EBITDA: SEK -3,680k (prior year: SEK -973k); interim period: SEK -9,204k (prior year: SEK -4,732k).

• Q2 operating result/EBIT: SEK -4,144k; interim period: SEK -10,263k.

• Q2 result before tax: SEK -4,557k; interim period: SEK -11,088k.

• Non-recurring costs of SEK 1.5 million related to CEO severance impacted results.

Outlook and guidance

• Second half of the year expected to show stronger revenue, driven by new product launches and increased tender activity.

• Improving gross margins anticipated as portfolio expands and fixed costs are offset.

• Focus remains on reaching EBITDA breakeven as a foundation for long-term growth.